CatalystDerivatives
KRYSTAL BIOTECH OUTLINES $175M-$195M 2026 NON-GAAP OPEX RANGE AS VYJUVEK EXPANDS OVERSEAS PRICING TALKS - SEEKINGALPHA
KRYSTAL BIOTECH OUTLINES $175M-$195M 2026 NON-GAAP OPEX RANGE AS VYJUVEK EXPANDS OVERSEAS PRICING TALKS - SEEKINGALPHA